Lenz Robert A. 4
4 · Neumora Therapeutics, Inc. · Filed Sep 19, 2024
Insider Transaction Report
Form 4
Lenz Robert A.
Head of R&D
Transactions
- Sale
Common Stock
2024-09-17$11.81/sh−30,788$363,736→ 339,205 total - Sale
Common Stock
2024-09-18$12.09/sh−10,676$129,091→ 328,529 total
Footnotes (3)
- [F1]The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on June 12, 2024.
- [F2]This transaction was executed in multiple trades in prices ranging from $11.5985 to $12.08, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- [F3]This transaction was executed in multiple trades in prices ranging from $12.00 to $12.18, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.